Citation: I. Adriaenssen et al., RESOURCE IMPLICATIONS OF PACLITAXEL CISPLATINUM VERSUS CYCLOPHOSPHAMIDE/CISPLATINUM IN THE TREATMENT OF ADVANCED OVARIAN-CANCER/, European journal of cancer, 33, 1997, pp. 1-1
Authors:
AWADA A
VANVRECKEM A
PARIDAENS R
BRUNING PF
KLIJN J
TOMIAK E
VINHOLES J
ROY JA
KUSENDA Z
BOES GH
VANGLABBEKE M
PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER, European journal of cancer, 33(8), 1997, pp. 1173-1176
Authors:
BERTELSEN K
KAERN J
SIMONSEN E
PICCART MJ
BOES GH
TIMMERS P
ROY JA
PECCORELLI S
STUART NCICG
JAMES K
CASSIDY J
KAYE S
Citation: K. Bertelsen et al., IS CISPLATIN-TAXOL (PT) THE STANDARD TREATMENT IN ADVANCED OVARIAN-CANCER - THE NOCOVA, European journal of cancer, 33, 1997, pp. 614-614
Authors:
PARIDAENS R
BRUNING P
KLIJN J
GAMUCCI T
BIGANZOLI L
VANVRECKEM A
BOES GH
CURRAN D
PICCART M
Citation: R. Paridaens et al., TAXOL (T) VERSUS DOXORUBICIN (D) AS FIRST-LINE CHEMOTHERAPY (CT) IN ADVANCED BREAST-CANCER (ABC) - AN EORTC RANDOMIZED STUDY WITH CROSSOVER, European journal of cancer, 33, 1997, pp. 645-645
Authors:
ARNAUD JP
NORDLINGER B
BOSSET JF
BOES GH
SAHMOUD T
SCHLAG PM
PENE F
Citation: Jp. Arnaud et al., RADICAL SURGERY AND POSTOPERATIVE RADIOTHERAPY AS COMBINED TREATMENT IN RECTAL-CANCER - FINAL RESULTS OF A PHASE-III STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER, British Journal of Surgery, 84(3), 1997, pp. 352-357
Authors:
GREGOR A
DRINGS P
RINALDI M
SCHUSTER L
BURGHOUTS J
POSTMUS PE
DALESIO O
KIRKPATRICK A
BOES GH
VANZANDWIJK N
Citation: A. Gregor et al., ACUTE TOXICITY OF ALTERNATING SCHEDULE OF CHEMOTHERAPY AND IRRADIATION IN LIMITED SMALL-CELL LUNG-CANCER IN A PILOT-STUDY (08877) OF THE EORTC LUNG-CANCER COOPERATIVE GROUP, Annals of oncology, 6(4), 1995, pp. 403-405
Authors:
MONFARDINI S
SORIO R
BOES GH
KAYE S
SERRAINO D
Citation: S. Monfardini et al., ENTRY AND EVALUATION OF ELDERLY PATIENTS IN EUROPEAN ORGANIZATION FORRESEARCH AND TREATMENT OF CANCER (EORTC) NEW-DRUG-DEVELOPMENT STUDIES, Cancer, 76(2), 1995, pp. 333-338